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Abstract 
            Context.  Advances being made in improving access to HIV drugs in resource poor 
countries mean HIV patients are living longer, and, therefore, experiencing pain over a longer 
period of time.  There is a need to provide effective interventions for alleviating and managing 
pain. 
Objectives. To assess whether a pain educational intervention compared to usual care 
reduces pain severity and improves pain management in patients with HIV/AIDS and their 
family carers. 
Methods.  This was a randomized, parallel group, superiority trial conducted at HIV and 
palliative care clinics of two public hospitals in Malawi. One hundred eighty-two adults with 
HIV/AIDS (stage III or IV) and their family carers participated; carer participants were those 
individuals most involved in the patient’s unpaid care. The educational intervention comprised a 
30-minute face-to-face meeting, a leaflet and a follow-up telephone call at two weeks. The 
content of the educational intervention covered definition, causes and characteristics of pain in 
HIV/AIDS, beliefs and myths about pain and pain medication, assessment of pain, and 
pharmacological and non-pharmacological management. The primary outcome was average pain 
severity measured by the Brief Pain Inventory-Pain Severity. Assessments were recorded at 
baseline before randomization and at eight weeks after randomization. 
Results. Of the 182 patient/carer dyads randomly allocated, 157 patient/carer dyads 
completed the trial.  Patients in the intervention group experienced a greater decrease in pain 
severity (mean difference 21.09, points, 95% confidence interval 16.56, 25.63; P <0.001). 
Conclusion. A short pain education intervention is effective in reducing pain and 
improving pain management for Malawian people living with HIV/AIDS and their family carers. 
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Introduction 
Advanced HIV infection and its treatment with antiretroviral therapy are associated with 
physical and psychological symptoms [1, 2]. These require focused assessment and management 
using locally available resources and interventions to optimize quality of life for patients and 
their carers [3, 4]. The negative impact of pain on quality of life has been documented in many 
studies [5, 6]. Pain is a major problem for people living with HIV/AIDS [7-9]. Pain is the most 
frequent and main cause of psychological distress [10, 11]. Experiencing pain can reduce 
adherence to drug regimens and quality of life for HIV/AIDS patients [12-16]. 
It is estimated that 35.3 million people were living with HIV/AIDS at the end of 2012 
[17, 18]. In the same year, there were 1.6 million deaths from AIDS, a reduction from 2.3 million 
deaths in 2005. In 2010, 1.4 million people began HIV medication, an increase in the number of 
people receiving treatment from the previous year of 27%. Greater access to effective treatment 
largely explains some of this decline in HIV/AIDS mortality [19]. 
Sub-Saharan Africa has 10% of the world’s population, but it is home to 69% of all 
people living with HIV/AIDS, making it the worst affected region [17, 18]. Antiretroviral 
therapy can dramatically increase survival and years of healthy life, but is unavailable in many 
parts of the region [19]. In 2010 in sub-Saharan Africa, the number of individuals treated with 
antiretroviral medication increased from 37% in 2009 [20] to 49% of the population eligible for 
treatment [21]. 
In Malawi the prevalence of HIV/AIDS is estimated at 11% of the population aged 15 to 
49 years, with around 910,000 people living with HIV/AIDS at the end of 2011 [18].  
Approximately 250 people are newly infected each day [21], and at least 70% of Malawi's 
hospital beds are occupied by HIV/AIDS patients [22], making Malawi the twelfth worst 
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affected country with HIV/AIDS worldwide [23]. However, there was a decline in HIV/AIDS 
prevalence from 14% in 2003 to 10% in 2011 predominantly because of increased access to 
antiretroviral therapy and preventive strategies [24]. Substantial progress has been made in the 
provision of HIV medication [25]. The involvement of nurses in the prescription and 
administration of medications and training health assistants to provide HIV counseling services 
has resulted in a greater proportion of patients starting HIV treatment within three weeks of 
diagnosis [26]. This has resulted in increased antiretroviral coverage to 67% in 2011 [24, 25]. 
Adequate pain control remains a challenge for HIV/AIDS patients and has an impact on 
their quality of life [14, 15]. Pain is experienced throughout the disease trajectory, severity being 
associated with later World Health Organization (WHO) clinical stage [2, 27-29], with an 
estimated 80% of people with advanced HIV infection experiencing severe pain [30]. Pain is also 
experienced as an effect of HIV medication [31, 32]. With advances being made in improving 
access to HIV drugs in resource poor countries, HIV patients are living longer, and, therefore, 
experiencing pain over a longer period [33, 34]. There is a need to provide effective 
interventions to HIV/AIDS patients in alleviating and managing pain. A systematic review [35] 
reported that self-management education programs for people living with HIV/AIDS results in 
short-term improvements in physical and psychosocial health and knowledge. However, all the 
trials reviewed were conducted in the U.S. and China where the health context is very different 
and none of these trials directly involved unpaid carers, a group likely to play a key role in the 
management of pain of those they care for. 
Methods 
Study Design 
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The pain education intervention study was a two-center, randomized, parallel group, 
wait-list controlled superiority trial. A detailed study protocol has been published [36]. 
Setting and Participants 
From October 2012 to June 2013, we recruited participants at HIV and palliative care 
clinics within two public hospitals (Ekwendeni and Mzuzu Central) in northern Malawi. Both 
hospitals provide inpatient, clinic-based and home-based care for people with HIV/AIDS that 
includes active treatment and palliative care.  Participants were people living with HIV/AIDS 
who had a primary carer who was identified as the individual most involved in their care. They 
were adults aged 18 years or over. All participants were able to read and write in English or 
Tumbuka (the vernacular language used in the northern part of Malawi). Participants were at 
WHO clinical stages III or IV of HIV/AIDS, or with a CD4 cell count of less than 350 cells, 
when the presence of pain and other symptoms is more likely because of opportunistic infections 
or side effects of HIV treatment.  We excluded people living with HIV/AIDS if they had health 
problems that hindered cognition and communication such as HIV-associated dementia. 
Recruitment 
People living with HIV/AIDS in Malawi typically visit the hospital (palliative care clinics 
and HIV clinics) with their family members. Posters about the study entitled “Pain Education 
Study” were prominently displayed in the clinics. Additionally, the first author (K.N.) or staff in 
these clinics informed patients about the study and provided them with information sheets. 
Potential participants were encouraged to discuss the study with family members before making 
a decision to take part. Those interested in taking part in the study were asked by K.N. to provide 
written informed consent. A checklist was used to confirm that all criteria for study eligibility 
were met. 
  
7 
Randomization, Concealment of Allocation and Blinding 
Baseline assessments were conducted by K.N. prior to randomization. Randomisation 
was implemented by K.N. using opaque, sealed and numbered envelopes. The envelope was 
opened in the presence of the participant. Participants had a 50% chance of being allocated to 
either the pain education intervention group or usual care group. In order to limit imbalance 
between the treatment groups, participants were randomly assigned with block randomization 
using the “ralloc” command in Stata v. 12 [37]. This allocates participants at random in blocks of 
sizes 2, 4, 6, 8 and 10, with block sizes allocated unequally in the ratio of 1:4:6:4:1 (Pascal's 
triangle). 
Randomization was stratified by recruiting hospital. K.N. was not involved in the 
preparation of envelopes and was blinded to block size. A.A. prepared the envelopes and had no 
contact with the study participants, nor was he involved in recruitment. Owing to the nature of 
the intervention, participants and K.N. knew the treatment arm to which they were allocated, but 
the nurses who conducted follow-up outcomes were blinded to this information. Participants 
were told not to inform the assessors about treatment allocation. Assessors were asked if 
participants had told them of their group allocation after completion of outcome assessments to 
assess the success or failure of blinding. 
Intervention and Comparator Groups 
Pain Education Intervention. The nurse-led pain education intervention was informed by 
a biopsychosocial approach [38] to the management of pain among people with HIV/AIDS. It 
was designed to provide a systematic and proactive approach to assist people with HIV/AIDS 
and their carers to better understand and manage pain. The intervention consisted of a health 
education session delivered face-to-face by K.N., a Malawian registered nurse and specialist in 
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palliative care, to the individual patient-carer dyads (Table 1). The face-to-face session took 
approximately 30 minutes in a quiet room within the palliative care or HIV/AIDS clinic where 
the participant was recruited. The components of the pain education intervention are listed in 
detail elsewhere [36] but included a discussion of HIV/AIDS-related pain, beliefs and myths 
about pain and pain medication, ways to assess pain, and potential pharmacological and non-
pharmacological methods to manage pain. A leaflet entitled “All About Your Pain” was given to 
participants, who were given the opportunity to look through it (Appendix, available at 
jpsmjournal.com). K.N. then discussed the contents of the leaflet with the participants and they 
were both encouraged to ask questions. Participants received a phone call reminder from K.N. 
after two weeks to inquire whether they had any further questions after the face-to-face 
discussion and reading the leaflet. Phone contacts typically lasted no more than five minutes. In 
order to minimize possible contamination between two groups, participants were asked not to 
share the leaflet with others. The features of usual care and the pain education intervention are 
explained in Table 1. There was no intention to systematically manage pain differently between 
the two groups but one consequence for those in the pain education intervention group may have 
been to seek out additional treatments to manage their pain. 
The leaflet drew on the evidence base and related literature for cancer pain management 
[39, 40] and HIV/AIDS pain management in Africa [41, 42] and pain management in Malawi 
[43]. Health care workers, HIV/AIDS patients and family carers were involved in the 
development of the leaflet in terms of its design, content, technical characteristics, and 
readability. 
The leaflet was in the form of a double-sided A4 page formatted so that it could be gate-
folded into two for ease of use. It was printed in color and had Illustrations to improve clarity 
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and understanding. Diagrams and pictures were used to enhance understanding and to motivate 
the reader. The leaflet was pilot-tested among 10 patients and 10 family carers to ensure that the 
content was readable and understandable. 
Usual Care.  Information relating to pain management is typically provided in a 
responsive rather than proactive manner and ad hoc rather than systematic, with the focus 
restricted to pharmacological treatment of pain. Pain assessments are not usually conducted in a 
systematic way and not recorded routinely. It is unusual for this information to be routinely 
shared with patients and/or their carers. 
Outcomes 
The primary outcome was average pain severity measured using the Brief Pain Inventory  
(BPI-PS) [44]. Secondary outcomes were pain interference with daily activities measured using 
the mean score of the seven pain interference items of the Brief Pain Inventory (BPI-PI) [45], 
knowledge of pain management  measured using the knowledge subscale of the Patient Pain 
Questionnaire PPQ-K [46], and  quality of life measured using the APCA African Palliative care 
Outcomes Scale (POS) [47, 48]. For carers, knowledge of pain management was measured using 
the knowledge subscale of the Family Pain Questionnaire (FPQ-K) [49], carer motivation was 
measured using the Picot Caregiver Rewards Scale (PCRS) [50], and quality of life was 
measured using the APCA African POS [47]. All outcomes were self-reported. If participants 
were unable to self-complete after careful and standardized explanation of individual items, they 
were asked the question verbally and interviewers recorded their responses. While the BPI [51] 
and APCA African POS [52] have both been used previously in Sub-Saharan African 
populations, use of the PPQ, FPQ and PCRS has been restricted to populations in Western 
countries. Our experience immediately prior to trial recruitment of piloting these scales as part of 
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the questionnaire among 10 patients and 10 carers suggests that they are acceptable to and 
understood by members of the population of patients and carers from which our sample was 
recruited. 
All outcome measures were conducted at baseline and eight weeks after delivery of the 
intervention. Eight weeks was considered sufficient time to observe any effect of the intervention 
and long enough to be considered clinically important. Outcomes were transposed to a 0 to 100 
scale, with higher scores indicating a more “positive’ outcome”; hence, a participant’s individual 
score represented a percentage of the best possible score for that outcome. 
Sample Size 
We wished to be able to detect a mean difference of 10% between the treatment groups in 
the primary outcome measure (average pain severity on the BPI). A 10% improvement is the 
difference considered the lower limit of changes considered clinical important [53]. Using a P-
value cut-off of 0.05 to determine a statistically significant result, 76 people per arm of the trial 
were needed to complete the study to give 80% power to detect such a difference. This is based 
on a review [54] that suggests that education-based interventions are able to produce this level of 
improvement in pain reduction, and that a standard deviation of 2.2 points is a liberal estimate of 
variability. To allow for 15% attrition, we aimed to recruit 182 participants to the trial. 
Statistical Analysis 
All patients and carers were analyzed according to the group to which they were 
randomized, although the use of strict intention-to-treat analysis is only possible where there is 
no loss to follow-up [55, 56]. We compared treatment groups in terms of our primary outcome 
measure (average pain severity using the BPI-PS treated as a continuous measure) using a linear 
regression model, with baseline BPI and treatment group and recruitment center as covariates. 
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Analysis of each of the six secondary outcomes (BPI-PI, PPQ-K, APCA African POS patient 
score, FPQ-K, PCRS, APCA African POS carer score) were conducted using six equivalent 
models, with estimates of treatment effect conditional on the value of the outcome at baseline. 
Sensitivity analysis was performed as follows: we conducted secondary analyses that 1) adjusted 
for variables that were considered potential predictors of outcome (age, gender, number of pain 
medications at baseline) assuming missing at random, and 2) considered plausible scenarios for 
departures from the missing at random assumption using the Stata command “rctmiss” [56]. 
These scenarios were for all outcomes using scores of the mean outcome plus and minus 20 
points for both arms and individual arms. All models included recruitment center as a covariate. 
All analyses were conducted using Stata version 12 [37]. 
Ethical Approval 
The study was approved by the University of Nottingham Medical School Research 
Ethics Committee (SNMP 11042012) and the National Health Sciences Research Committee of 
Malawi (NHSRC 1023). 
Results 
Of the 308 potential patient/carer dyads assessed, 182 were eligible, consented to 
participate and completed baseline measures (Fig. 1). Ninety-two were randomized to the pain 
education intervention and 90 were randomized to usual care. Of these, 15 patient/carer dyads 
and 10 carers were lost to follow-up. Reasons for attrition in the pain education group were 
patient having died before follow-up assessments (n=4), no transport (n=2), untraceable (n=1) 
and moved away (n=1). Reasons for attrition in the usual care group were: untraceable (n=2), 
moved away (n=4) and patient too unwell (n=1). Reasons for carer loss to follow-up in the pain 
education group and usual care group were the same: carer too busy (n=2) and no transport 
  
12 
(n=3). Of the 167 patients and 157 carers who completed the trial, complete data were available 
for all outcomes. 
Baseline Characteristics 
Pain education and usual care groups were similar at baseline in terms of 
sociodemographic profile except for gender; there were 43 (46.7%) male patients in the pain 
education group compared with 56 (62.2%) male patients in the usual care group (Table 2). 
There were also differences in carer relationship to the patient; there were 35 (38.0%) spousal 
carers in the pain education group and 44 (48.9%) spousal carers in the usual care group. At 
baseline, the two groups of patient/carer dyads were broadly similar in terms of the seven 
outcome measures. 
Delivery and Receipt of the Intervention 
The intervention was delivered by K.N. All the participants (n=92) randomized to the 
pain education intervention attended a 30-minute face-to-face discussion and received a leaflet. 
Of these, 59 participants received the phone call reminder intervention at week two. Because of 
poor telephone network coverage, some participants did not receive a phone call (n=19) but had 
physical contact with K.N. during their visit to the clinic at week two. Of the 59 participants who 
received a phone call, four also had face-to-face contact with K.N. at the clinic, where they were 
reminded to read the leaflet and clarification was provided in response to their questions. 
Primary Outcome 
Both groups had reduced average pain severity at follow-up. However, those in the pain 
education group had a mean change of 40.95 (SD 23.78) while the usual care group had a mean 
change of 19.27(SD 25.27) (Table 3). When adjustments were made for baseline average pain 
severity score, recruitment center, age, gender and number of pain medications, participants in 
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the pain education group reported less severity of pain compared to those in the usual care group 
(mean difference 21.25, 95% confidence interval [CI] 16.7, 25.8; P <0.001). 
Secondary Outcomes 
Participants in the pain education group had significantly less pain interference than the 
usual care group at follow-up (adjusted mean difference 24.5, 95% CI 19.61, 29.38; P<0.001). 
Patients in the pain education group reported greater improvement in knowledge than patients in 
the usual care group at follow-up (adjusted mean difference 20.39, 95% CI 17.51, 23.27; 
P<0.001). At follow-up, participants in the pain education group experienced better quality of 
life than participants in the usual care group (adjusted mean difference 28.76, 95% CI 24.62,  
32.91; P<0.001) (Table 3). 
Carers in the pain education group reported greater improvement in knowledge than 
carers in the usual care group at follow-up (adjusted mean difference 20.32, 95% CI 17.37,  
23.28; P<0.001) (Table 4). Carers in the pain education group reported greater motivation to 
provide care than carers in the usual care group at follow-up (adjusted mean difference 7.64, 
95% CI 5.15, 10.13; P<0.001), as well as a better quality of life (adjusted mean difference 34.16, 
95% CI 30.15, 38.17; P<0.001). 
Sensitivity Analysis 
In all the scenarios tested using various departures from the missing at random 
assumption, none altered the interpretation of better outcomes for the pain education group. 
Discussion 
In this randomized controlled trial, we found evidence that pain education intervention 
consisting of a face-to-face discussion, leaflet and two-week follow-up phone call reduced pain 
severity, reduced pain interference with daily activities, improved patient knowledge of pain 
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management and patient quality of life. We also found evidence that the intervention improved 
carers’ pain knowledge of pain management, quality of life, and motivation to provide care. The 
results are consistent with other studies of interventions to enhance self-care that have found 
improvement in pain management [57, 58], better knowledge about pain [59-61], improved pain 
control [58, 59, 62, 63] and less pain interference with daily activities [62, 63] although the form, 
content and context of these interventions were different and were administered among cancer 
patients.  Our findings are different from those of a study conducted among HIV/AIDS patients 
[64] that found decreased quality of life when medication reminders were given, and to a trial 
that found no effect of an educational intervention to enhance self-management skills [65]. Our 
finding of improved knowledge about pain among people with HIV/AIDS is consistent with a 
large trial [66] that found significant improvement in knowledge among HIV/ AIDS participants 
following an HIV medication adherence intervention.  The effect of the intervention on family 
carers is also consistent with other studies among family carers of people with cancer [67]  and 
dementia [68]. Previous studies of family carers also found that family members feel rewarded 
and more prepared in their caregiving role if education is provided to them [69, 70]. 
Strengths and Limitations 
To our knowledge, this is the first randomized controlled trial to be conducted in sub-
Saharan Africa to recruit patient and carer dyads. The dearth of research into HIV/AIDS-related 
pain in African populations means that, for some outcomes, we have had to infer validity from 
validation studies conducted outside of Africa. The sample size of 182 was larger than other 
trials of pain education interventions, which have, hitherto, been conducted in Western countries 
and targeting cancer patients [57, 58, 62] or cancer patients and their carers [60, 63]. Recruitment 
to our trial was successful and attrition relatively low at 15% loss to follow-up. The main reasons 
  
15 
for loss to follow-up were death of the patient, patient transferred to another center, lack of 
transport, and carer being too busy. 
This was a complex intervention and the nature of the intervention meant that it was not 
possible to blind participants of group allocation; we cannot exclude the possibility that patients 
and carers in the pain education intervention group may have responded more positively as a 
result of getting greater attention. However, social desirability bias is likely to have been limited 
by the use of staff nurses, blinded to allocation, conducting outcomes although we cannot be sure 
that participants did not divulge that information. 
The follow-up measures were conducted eight weeks after randomisation; this was 
sufficient time to observe the effects of the intervention and is consistent with other pain 
education studies [71, 72].  However, we do not know whether the positive results we observed 
are likely to be sustained beyond that time frame. Pain education participants were asked not to 
report the face-to face discussion and not to pass the leaflet to any staff member or other patients 
to minimize contamination between two groups. However the possibility of contamination 
cannot be excluded because participants lived in the same community where we had no means to 
prevent them from sharing the leaflet. Clustering the participants and randomizing according to 
some natural grouping such as area or clinic could have avoided contamination thereby reducing 
type II error [73], but the scale of such a study would have required resources exceeding those 
available to us. 
Conclusion 
The current practice in HIV/AIDS and palliative care clinics in much of sub-Saharan 
Africa does not prioritize the provision of health-related information among patients. This study, 
conducted in Malawi, has provided strong evidence that a simple pain education intervention 
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comprising a leaflet and verbal advice can reduce pain severity and interference, and improve 
pain knowledge and quality of life outcomes among HIV/AIDS patients. To build on these 
important findings, future research should include a health economic analysis. This would 
establish whether the benefits observed for patients and carers are accompanied by benefits to the 
wider health economy. 
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Table 1. Features of Usual Care and the Pain Educational Intervention 
Element Usual Care/Wait-List 
Control 
Pain Education 
Intervention 
General description Unstructured verbal 
information 
Leaflet-based information, 
advice, explanation and 
discussion 
Form General information on the 
treatment prescribed and 
instructions to be followed, 
responsive information from 
staff nurses 
Information leaflet distributed 
“All About Your Pain” 
including 30-minute face-to-
face verbal instructions and 
advice on pain assessment 
and management, phone call 
reminder after two weeks 
Content General information about 
HIV/AIDS medication and 
treatment compliance 
Specific information about 
procedure on pain assessment 
and classification using pain 
scales and pain diagrams, 
including pain management 
using WHO analgesic ladder 
and specific drugs on each 
step 
Written materials None Leaflet with simplified text 
information and diagrams, 
pictures/photos for quick 
reference 
Method of delivery General staff members K.N. 
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Table 2. Baseline Characteristics of Participants (N=182) Randomized to the Pain 
Education Intervention or Usual Care 
Variables Pain Education Intervention (n=92) Usual Care (n=90) 
Patient participants   
Mean (SD) age in yrs 40.5 (11.3) 41.3 (11.65) 
Gender   
         Male 43 (46.74) 56 (62.22) 
         Female 49 (53.26) 34 (37.78) 
Marital status   
          Married 61 (66.3) 58 (64.44) 
          Single 11 (11.96) 13 (14.44) 
          Divorced/separated 11 (11.96) 10 (11.11) 
          Widow/widower 9    (9.78) 9 (10) 
Education   
          Primary school 21 (22.83) 14 (15.56) 
          High school 66 (71.74) 72 (80) 
          College/University 5 ( 5.43) 4 (  4.44) 
BPI pain measures, mean (SD)   
          Average pain severity 50.76 (24.86) 51.22 (27.1) 
          Pain interference 49.91 (27.97) 49.46 (29.48) 
Pain knowledge. Mean (SD)   
          PPQ-K subscale 67.78 (16.61) 66.24 (18.84) 
Quality of life mean (SD)   
       APCA African POS subscale 44.78 (22.79) 48.92 (20.5) 
Carer participants   
Mean (SD) age in yrs 41.1 (11.7) 42.6 (SD 11.4) 
Gender   
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          Male 14 (15.56) 19 (21.11) 
          Female 76 (84.44) 71 (78.89) 
Marital status   
          Married 78 (84.78) 81 (90) 
          Single 10 (10.87) 6 ( 6.67) 
          Divorced/separated 1 (  1.09) 1 ( 1.11) 
          Widow/widower 3  (  3.26) 2 ( 2.22) 
Education   
          Primary 21 (22.8) 22 (24.4) 
          High school 66 (71.7) 64 (71.1) 
          College/University 5 (  5.4) 4 (  4.4) 
Carer relationship to patient   
          Spouse 35 (38.04) 44 (48.9) 
          Sibling 27 (29.4) 20 (22.2) 
          Son/daughter 10 (10.9) 4   (4.4) 
          Friend 0 2   (2.2) 
          Parent 12 (13) 14  (15.6) 
          Other 8 (8.7) 6  ( 6.7) 
Pain knowledge, mean (SD)   
          FPQ-K subscale 65.29 (16.93) 64.59 (18.53) 
Motivation. mean (SD)   
          PCRS 78.91 (11.29) 79.41 (11.02) 
Quality of life mean (SD)   
        APCA African POS subscale 44.2 (18.95) 45.26 (18.55) 
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Table 3. Patient Outcomes: Average Pain Severity on the BPI-PS for Pain Education and 
Usual Care Groups  
Primary 
Outcome 
Pain 
Education 
(n=84) 
Usual 
Care 
(n=83) 
Adjusted for Baseline 
Average Pain Severity and 
Recruitment Center 
Adjusted for Baseline Average 
Pain Severity, Recruitment 
Center, Age, Gender and Number 
of Pain Medications 
Mean 
Difference 
(95% CI) 
P-value Mean 
Difference 
(95% CI) 
P-value 
BPI-PS subscale       
Mean (SD) 
average pain 
severity score 
      
At baseline 
(n=182) 
50.76 
(24.86) 
51.22 
(27.1) 
    
At follow-up 
(n=167) 
92.62 
(8.23) 
71.69 
(21.18) 
    
Mean change (SD) 
from baseline 
40.95 
(23.78) 
19.27 
(25.27) 
21.09 
(16.56,  
25.63) 
<0.001 21.25 (16.7, 
25.8) 
<0.001 
Secondary 
Outcomes 
Pain 
Education 
(n=84) 
Usual 
Care 
(n=83) 
Adjusted for Baseline 
score and Recruitment 
Center 
Adjusted for Baseline Score, 
Recruitment Center, Age, Gender 
and Number of Pain Medications 
BPI-PI subscale       
Mean (SD) pain 
interference 
      
At baseline 
(n=182) 
49.91 
(27.97) 
49.46 
(29.48) 
    
At follow-up 
(n=167) 
93.67 
(9.33) 
69.24 
(25.21) 
    
Mean change (SD) 
from baseline 
42.5 
(25.91) 
18.42 
(23.92) 
24.32 
(19.33, 
29.32) 
<0.001 24.5 (19.61, 
29.38) 
<0.001 
PPQ-K subscale       
Mean pain       
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knowledge 
At baseline 
(n=182) 
67.78 
(16.61) 
66.24 
(18.84) 
    
At follow-up 
(n=167) 
92.63 
(8.16) 
71.98 
(15.21) 
    
Mean (SD) change 
from baseline 
25.63 
(15.5) 
6.32 
(11.00) 
20.05 
(17.25,  
22.86) 
<0.001 20.39 (17.51, 
23.27) 
<0.001 
APCA African 
POS-patient 
subscale 
      
Mean (SD) POS       
At baseline 
(n=182) 
44.78 
(22.79) 
48.92 
(20.5) 
    
At follow-up 
(n=167) 
90.58 (9.0) 63.37 
(19.46) 
    
Mean (SD) change 
from baseline 
45.44 
(22.58) 
14.46 
(18.77) 
28.32 
(24.12,  
32.53) 
<0.001 28.76 (24.62, 
32.91) 
<0.001 
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Table 4. Carer Outcomes: Pain Knowledge, Motivation and Quality of Life for Carer Participants 
Outcomes Pain 
Education 
(n=79) 
Usual 
Care 
(n=78) 
Adjusted for Baseline 
Score and Recruitment 
Center 
Adjusted for Baseline Score, 
Recruitment Center, Age, Gender 
and Number of Pain Medications 
Mean 
Difference 
(95% CI) 
P-value Mean 
Difference (95% 
CI) 
P-value 
FPQ-K subscale       
Mean pain 
knowledge 
      
At baseline (n=182) 65.29 
(16.93) 
64.59 
(18.53) 
    
At follow-up (n=157) 91.36 
(7.8) 
70.26 
(15.88) 
    
Mean (SD) change 
from baseline 
27 (15.8) 7.17 (9.8) 20.51 (17.58,  
23.44) 
<0.001 20.32 (17.37, 
23.28) 
<0.001 
PCRS       
Mean (SD) 
motivation 
      
At baseline (n=182) 78.91 
(11.29) 
79.41 
(11.02) 
    
At follow-up (n=157) 97.13 
(5.87) 
89.52 
(11.14) 
    
Mean (SD) change 
from baseline 
18.01 
(11.96) 
10.18 
(8.48) 
7.7 (5.26, 
10.14) 
<0.001 7.64 (5.15, 
10.13) 
<0.001 
APCA African 
POScarer subscale 
      
Mean (SD) POS       
At baseline (n=182) 44.2 
(18.95) 
45.26 
(18.55) 
    
At follow-up (n=157) 92.66 
(8.84) 
58.55 
(17.94) 
    
Mean (SD) change 
from baseline 
47.68 
(18.86) 
13.42 
(16.63) 
34.13 (30.16,  
38.09) 
<0.001 34.16 (30.15, 
38.17) 
<0.001 
 
 
Fig. 1.  Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patients and carers 
throughout the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=308) 
Excluded (n=126) 
 No carer (n=45) 
 Unable to read and write (n=15) 
 Outside catchment area (n=15) 
 Cognitively impaired (n=4) 
 Died before recruitment (n=10) 
 Declined (n=37) 
  
 
 
 
Allocated to usual 
care (n=90) 
Received usual care 
(n=90) 
 
Patient and carer lost to 
follow-up (n=7)  
   Untraceable (n=2)                   
   Moved away (n=4)                  
   Patient unwell (n=1)   
 
Carer loss to follow-up 
(n=5) 
 Too busy (n=2) 
  No transport (n=3)    
Patient and carer lost to 
follow-up (n=8)  
  No transport (n=2)              
  Patient died (n=4)              
  Untraceable (n=1)              
  Moved away (n=1) 
 
Carer loss to follow-up 
(n=5) 
   Too busy (n=2) 
   No transport (n=3)          
 
                 Randomized (n=182) 
Allocated to pain 
education intervention 
(n=92) 
Received allocated 
intervention (n=92) 
Followed-up and analyzed 
(n=78 patients and carers) 
(n=5 patients) 
Followed-up and analyzed 
 (n=79 patients and carers) 
 (n=5 patients) 
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This study is approved for the period of active recruitment requested. The
Committee also provides a further 5 year approval for any necessary work to be
performed on the study which may arise in the process of publication and peer
review.
You promptly inform the Chairman of the Research Ethics Committee of
(i) Deviations from or changes to the protocol which are made to eliminate
immediate hazards to the research subjects.
(ii) Any changes that increase the risk to subjects and/or affect significantly the
conduct of the research.
(iii) All adverse drug reactions that are both serious and unexpected.
(iv) New information that may affect adversely the safety of the subjects or the
conduct of the study.
(v) The attached End of Project Progress Report is completed and returned when
the study has finished.
Yours sincerely
Dr Clodagh Dugdale
Chair, Nottingham University Medical School Research Ethics Committee
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